Black Diamond Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Black Diamond Therapeutics, Inc. (BDTX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-69.68-82.44-91.17-125.60-67.25-35.26
Depreciation & Amortization0.340.440.510.211.780.05
Stock Based Compensation10.639.6012.2014.047.770.00
Change in Working Capital-2.696.80-9.907.025.610.46
Change in Accounts Payable1.680.60-2.231.571.070.00
Change in Other Working Capital-4.382.81-7.675.453.970.00
Other Operating Activities-0.919.662.732.017.7510.04
Net Cash from Operating Activities-62.30-66.72-85.08-100.15-52.15-24.67
Investing Activities
Capital Expenditures0.000.03-0.19-2.710.140.02
Acquisitions0.090.000.000.000.000.00
Purchases of Investments-122.88-61.8953.55133.32-281.550.00
Sales/Maturities of Investments139.7578.17113.69133.32-281.550.00
Net Cash from Investing Activities16.9716.3553.37130.61-281.69-0.02
Financing Activities
Common Stock Issued24.4971.850.180.73213.840.00
Other Financing Activities1.050.000.000.00-1.280.00
Net Cash from Financing Activities25.5571.930.180.73214.94127.76
Summary
Net Change in Cash-19.7921.56-31.5431.19-118.89103.06
Cash at Beginning of Period57.0435.4867.0235.83154.7251.66
Cash at End of Period37.26-66.6635.4867.0235.83154.72
Free Cash Flow-62.30-66.66-85.27-102.86-52.29-24.70